Biogen Senses 'Interesting Opportunities' If Financial Markets Remain Challenging
This article was originally published in Scrip
Biogen Inc. has earmarked $100m for business development in 2016, an investment the company hopes to take advantage of if the financial markets continue to be challenging for young biotechs, driving down valuations for assets.
You may also be interested in...
Alzheimer's disease is a common and growing global menace that threatens health care budgets, but if a cure was ever found demand for the remedy it would likely swamp payer resources.
The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.
The European Medicines Agency has announced the names of the first four drugs to be accepted onto its new priority medicines scheme, including Biogen Inc.'s aducanumab for Alzheimer's disease. But the agency also turned down 14 other applications for PRIME eligibility.